Autologous Cell Therapy for Treatment of Fecal Incontinence
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 30
Summary
- Conditions
- Fecal Incontinence
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This study is designed to test the safety and feasibility of Autologous Muscle Derived Cells (AMDC) as a treatment for fecal incontinence in men and women. AMDC therapy seeks to allow remodeling of the external anal sphincter in patients with fecal incontinence from either defined structural defects...
This study is designed to test the safety and feasibility of Autologous Muscle Derived Cells (AMDC) as a treatment for fecal incontinence in men and women. AMDC therapy seeks to allow remodeling of the external anal sphincter in patients with fecal incontinence from either defined structural defects to or a generalized weakening of the external anal sphincter.
Tracking Information
- NCT #
- NCT01600755
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Manoj J Raval, MD St. Paul's Hospital
Get Well Soon